Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 1

Status

Terminated 2Unknown 1

Sponsor Class

OTHER 18INDUSTRY 3NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 9Recurrence 5Lymphoma, Non-Hodgkin 3Lymphoma, T-Cell 1Lymphoma, Mantle-Cell 1Lymphoma, B-Cell 1Leukemia, B-Cell 1Leukemia 1Hematologic Neoplasms 1Graft vs Host Disease 1Burkitt Lymphoma 1Bronchiolitis Obliterans Syndrome 1

Interventions

Rituximab 130Cyclophosphamide 41Bendamustine Hydrochloride 39venetoclax 25fludarabine 25obinutuzumab 24Lenalidomide 23ibrutinib 22Gemcitabine 22Vincristine 20Prednisone 20tositumomab I-131 19Doxorubicin 19plerixafor 14Dexamethasone 14Granulocyte Colony-Stimulating Factor 12pirtobrutinib 11Brentuximab Vedotin 11glofitamab 10tocilizumab 9pembrolizumab 9ibritumomab tiuxetan 9Etoposide 9Azacitidine 9polatuzumab vedotin 8parsaclisib 8copanlisib 8acalabrutinib 8Drug Therapy 8ublituximab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Lymphoma, Non-Hodgkin × Alemtuzumab × Clear all
NCT05557903 2022-09-28

Phase â…  Clinical Study of Anti-CD52 Monoclonal Antibody in NHL and T-PLL

Lanzhou Institute of Biological Products Co., Ltd

Phase 1 Unknown
71 enrolled
Lymphoid

Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, T-Cell

NCT00077961 2015-03-26

Rituximab Plus CAMPATH in Patients With Relapsed/Refractory Low-Grade or Follicular, CD20-positive, B-cell NHL

Sanofi

Phase 1/2 Terminated
49 enrolled
Lymphoid

Lymphoma, Non-Hodgkin

NCT00051701 2015-03-05

Phase I/II Study of CAMPATH in Patients With Relapsing or Refractory Non-Hodgkin's Lymphoma

Sanofi

Phase 1/2 Terminated
61 enrolled
Lymphoid

Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon âš¡